Group 1 - The company is focusing on expanding proteome coverage by targeting the detection of 18 to 20 amino acids and increasing sequencing read lengths on the Proteus prototype [1] - The list price for the Proteus has been set at $425,000 to align with academic grant cycles and assist potential customers with long-term capital budgeting [1] Group 2 - The strategic focus has shifted towards building a robust publication pipeline, with 5 manuscripts submitted in 2025 to showcase technology utility in clinical proteomics and pathogen detection [2] - The instrument placement program has successfully secured 17 new customers, which helps maintain user engagement and generate consumable revenue without requiring upfront capital [2] Group 3 - Performance in Q4 2025 was affected by capital spending headwinds, including uncertainties in NIH funding and customer hesitation regarding the next-generation platform [3] - Management is transitioning 2026 into a 'market preparation' year, prioritizing the upcoming Proteus launch over maximizing near-term Platinum Pro capital sales [3] - Revenue guidance for 2026 is approximately $1 million, reflecting a shift towards consumable utilization and service revenue rather than new hardware sales [3] - The commercial launch of Proteus is on track for the end of 2026, with prototype systems currently deployed for internal R&D and manufacturing scale-up [3] - Financial guidance indicates total cash usage of $93 million or less, with a balance sheet designed to fund operations into the second quarter of 2028 [3] - A 25% increase in consumable kit volume is expected in 2026 as the installed base matures and new placement-program users begin running experiments [3] - Future margin expansion is anticipated due to the cost-effectiveness of the Proteus passive nano-well architecture compared to current CMOS-based chips [3]